Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Merck
Baxter
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,259,186

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,259,186 protect, and when does it expire?

Patent 7,259,186 protects TRILIPIX and is included in one NDA.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: 7,259,186
Title:Salts of fenofibric acid and pharmaceutical formulations thereof
Abstract:In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients.In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
Inventor(s): Cink; Russell Drew (Grayslake, IL), Paterson, Jr.; Joseph B. (Vernon Hills, IL), Gao; Yi (Vernon Hills, IL), Zhang; Geoff G. Z. (Libertyville, IL), Long; Michelle A. (Libertyville, IL), Morris; John B. (Grayslake, IL), Rosenberg; Joerg (Ellerstadt, DE)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/880,851
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,259,186
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;

Drugs Protected by US Patent 7,259,186

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Baxter
Merck
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.